Replies to post #463572 on NorthWest Biotherapeutics Inc (NWBO)

[beartrap12]

Agree on both, MI. More likely suddenly they have a combo trial that makes their Keytruda more marketable, IMO. But would it extend their patent? I think that was the point of that paragraph. Perhaps.

[MI Dendream]

Bear, there are people here who know a lot more about patents than I do. I would assume that the combo patent extends the Keytruda patent life when used in combination with Dcvax. I also think that by 2030, Keytruda will rarely be used as mono therapy and it will most always be used with DCVax, especially if the research machine of Merck is driving the label expansion studies for the combo. But honestly, others know better than I.